mass cytometry
Navignostics Using Single-Cell Spatial Proteomics to Guide Oncology Treatment, Drug Development
Premium
The University of Zurich spinout is using Standard BioTools' Hyperion system for its analyses and recently raised CHF 7.5 million in seed funding.
Fluidigm Q2 Revenues Grow 19 Percent
The firm noted that its base product and service revenue (excluding COVID-19 testing) increased 33 percent year over year to $26.9 million.
Fluidigm CEO Chris Linthwaite said the company aims to further penetrate the diagnostic and clinical markets with both its microfluidics and mass cytometry businesses.
Fluidigm Q4 Revenues Grow 38 Percent on COVID-19-Driven Microfluidics Growth
The firm also announced a COVID-19 testing deal with George Mason University and a CyTOF supply and distribution agreement with Zhejiang PuLuoTing Health Technology in China.
Fluidigm Q3 Revenues Jump 50 Percent Driven by COVID-19 Testing
Fluidigm tallied $39.9 million in revenues compared to $26.5 million a year ago, and well above analysts' consensus estimate of $32.5 million.